Anti-CD3 monoclonal antibody - BTG/Millennium
Latest Information Update: 24 Sep 2021
At a glance
- Originator BTG; University of Oxford
- Class Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis; Transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Jul 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
- 16 Jul 2001 Preclinical development for Type-1 diabetes mellitus in United Kingdom (Unknown route)